Objective:To explore the therapeutic effect of Dingchuan Decoction combined with omazumab on acute attack of bronchial asthma.Methods:From January 2020 to November 2021,90 patients with acute asthma were treated in ou...Objective:To explore the therapeutic effect of Dingchuan Decoction combined with omazumab on acute attack of bronchial asthma.Methods:From January 2020 to November 2021,90 patients with acute asthma were treated in our hospital,which belonged to heat asthma syndrome according to TCM syndrome differentiation in our hospital.They were divided into control group and observation group with 45 cases in each group.The control group was treated with omazumab,while the observation group was treated with omazumab combined with Dingchuan Decoction.The changes of lung function,exhaled nitric oxide(FeNO),blood gas indexes and hematological indexes were observed before and after treatment,and the adverse reactions and asthma recurrence within 3 months were observed.At the same time,animal experiments were carried out to verify the curative effect of Dingchuan.Results:After treatment,the total effective rate,FeNO,pulmonary function,partial pressure of blood oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2)),interleukin-6(IL-6),interleukin-5(IL-5),immunoglobulin E(IgE)and asthma recurrence in 3 months in the observation group were better than those in the control group;There was no significant difference in pulse oxygen saturation(SaO_(2))and the incidence of adverse reactions between the two groups.Animal experiments show that Dingchuan Decoction can effectively improve lung inflammation.Conclusion:The combination of Dingchua Decoction and omazumab has a good curative effect in the treatment of acute attack of bronchial asthma,which can effectively improve the lung function and blood gas index of patients,reduce the levels of inflammatory factors and IgE,and has no obvious increase in adverse reactions,and effectively control the recurrence of asthma within 3 months.It can be used as an auxiliary maintenance treatment for patients with mild and moderate acute attack and clinical remission of asthma,thus reducing the utilization rate of hormones and having high application value.展开更多
OBJECTIVE:To compare the curative effects of heat-sensitive moxibustion with conventional drugs on chronic persistent asthma and seek a valuable therapy to replaceWestern Medicine.METHODS:The participants in this mult...OBJECTIVE:To compare the curative effects of heat-sensitive moxibustion with conventional drugs on chronic persistent asthma and seek a valuable therapy to replaceWestern Medicine.METHODS:The participants in this multi-center,randomized,and controlled study were randomly divided into two groups:group A(n=144),treated with heat-sensitive moxibustion(50 sessions)and group B(n=144),treated with Seretide(salmeterol50μg/fluticasone 250μg,twice a day).The scores of asthma control test(ACT),forced expiratory volume in 1 second(FEV1),peak expiratory flow(PEF),and attack frequency were measured after 15,30,60,and 90 days of treatment.Patients followed up3 and 6 months after treatment.RESULTS:There was a significant difference(P=0.0002)in the ACT score and lung function between the two groups after 3 months of treatment and(P=0.000 03)during the follow-up visits.In addition,heat-sensitive moxibustion reduced attack frequency in the period from inclusion to the6-month follow-up visit.CONCLUSION:This study shows that heat-sensitive moxibustion may have a comparable curative effect toSeretide(salmeterol/fluticasone)on asthma.展开更多
目的:研究龙麻金宁方对热哮大鼠气道重塑及其肺组织中蛋白激酶B(PKBm RNA)、成纤维细胞α-平滑肌肌动蛋白(α-SMA m RNA)、血小板衍生因子(PDGF)、I、III胶原蛋白表达水平的影响。方法:雄性SD大鼠,70只,随机分成以下7组:正常组、模型组...目的:研究龙麻金宁方对热哮大鼠气道重塑及其肺组织中蛋白激酶B(PKBm RNA)、成纤维细胞α-平滑肌肌动蛋白(α-SMA m RNA)、血小板衍生因子(PDGF)、I、III胶原蛋白表达水平的影响。方法:雄性SD大鼠,70只,随机分成以下7组:正常组、模型组、地塞米松组、麻杏石甘汤组以及龙麻金宁高、中、低剂量组,每组10只。在第1天和第8天,以10%卵蛋白腹腔注射致敏及细菌脂多糖(LPS)滴鼻制热(终浓度400μg·m L-1)复制大鼠热哮模型。第15天开始1%卵蛋白雾化激发,连续7 d,第21天模型复制成功,开始治疗。正常组、模型组每天给予等量蒸馏水灌服,地塞米松组、麻杏石甘汤组、龙麻金宁高、中、低剂量组按人体与大鼠体表面积换算比折算剂量灌胃,灌胃4周后解剖大鼠并取出肺组织。采用HE染色法观察肺组织的病理形态学改变;采用免疫组化法观察肺组织的中、小气道I、III胶原蛋白的阳性表达;采用酶联免疫吸附反应定量肺组织的PDGF含量;采用逆转录-聚合酶链反应以半定量测定PKBm RNA、α-SMA m RNA的表达丰度。结果:与正常组比较,模型组发生明显肺组织炎症反应和气道重塑现象,α-SMAm RNA、PKBm RNA、PDGF、I、III胶原表达水平显著升高(P<0.01);龙麻金宁高、中、低剂量治疗组与模型组比较,α-SMAm RNA、PKBm RNA、PDGF、I、III胶原表达水平显著降低(P<0.01)。结论:龙麻金宁明显减轻热哮大鼠气道炎症反应,抑制热哮大鼠肺组织中α-SMA m RNA、PKBm RNA、PDGF、I、III胶原的表达,延缓气道重塑而治疗哮喘。展开更多
文摘Objective:To explore the therapeutic effect of Dingchuan Decoction combined with omazumab on acute attack of bronchial asthma.Methods:From January 2020 to November 2021,90 patients with acute asthma were treated in our hospital,which belonged to heat asthma syndrome according to TCM syndrome differentiation in our hospital.They were divided into control group and observation group with 45 cases in each group.The control group was treated with omazumab,while the observation group was treated with omazumab combined with Dingchuan Decoction.The changes of lung function,exhaled nitric oxide(FeNO),blood gas indexes and hematological indexes were observed before and after treatment,and the adverse reactions and asthma recurrence within 3 months were observed.At the same time,animal experiments were carried out to verify the curative effect of Dingchuan.Results:After treatment,the total effective rate,FeNO,pulmonary function,partial pressure of blood oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2)),interleukin-6(IL-6),interleukin-5(IL-5),immunoglobulin E(IgE)and asthma recurrence in 3 months in the observation group were better than those in the control group;There was no significant difference in pulse oxygen saturation(SaO_(2))and the incidence of adverse reactions between the two groups.Animal experiments show that Dingchuan Decoction can effectively improve lung inflammation.Conclusion:The combination of Dingchua Decoction and omazumab has a good curative effect in the treatment of acute attack of bronchial asthma,which can effectively improve the lung function and blood gas index of patients,reduce the levels of inflammatory factors and IgE,and has no obvious increase in adverse reactions,and effectively control the recurrence of asthma within 3 months.It can be used as an auxiliary maintenance treatment for patients with mild and moderate acute attack and clinical remission of asthma,thus reducing the utilization rate of hormones and having high application value.
基金Supported by the Major State Basic Research and Development Program of People's Republic of China(No.2009CB522902)National Key Technology R&D Program(No.2006BAI12B04-2)+2 种基金National Natural Science Foundation of China(No.81160453)National Natural Science Foundation of China(No.81202854)Jiangxi Key R&D Project
文摘OBJECTIVE:To compare the curative effects of heat-sensitive moxibustion with conventional drugs on chronic persistent asthma and seek a valuable therapy to replaceWestern Medicine.METHODS:The participants in this multi-center,randomized,and controlled study were randomly divided into two groups:group A(n=144),treated with heat-sensitive moxibustion(50 sessions)and group B(n=144),treated with Seretide(salmeterol50μg/fluticasone 250μg,twice a day).The scores of asthma control test(ACT),forced expiratory volume in 1 second(FEV1),peak expiratory flow(PEF),and attack frequency were measured after 15,30,60,and 90 days of treatment.Patients followed up3 and 6 months after treatment.RESULTS:There was a significant difference(P=0.0002)in the ACT score and lung function between the two groups after 3 months of treatment and(P=0.000 03)during the follow-up visits.In addition,heat-sensitive moxibustion reduced attack frequency in the period from inclusion to the6-month follow-up visit.CONCLUSION:This study shows that heat-sensitive moxibustion may have a comparable curative effect toSeretide(salmeterol/fluticasone)on asthma.
